Summary of Technova Conference Call Company Overview - **Company**: Technova - **Industry**: Life Sciences, specifically reagents for biotech, pharma, and diagnostics - **Founded**: 1996 by a scientist from Genentech - **Public Offering**: Took the company public in February 2021 Key Points and Arguments - **Market Position**: Technova is a leading provider of reagents for the life science community, serving over 3,000 customers in the U.S. [3][4] - **Growth Trajectory**: The company has historically grown at 12% since February 2009 and aims for a top-line growth of 20-25% due to clinical programs in the pipeline [4][47] - **Revenue Potential**: Technova is positioned to scale its business to $200-250 million in revenue without significant additional capital expenditures (CapEx) [4][41] - **Gross Margin**: 70% of every additional dollar in revenue contributes to the bottom line, indicating strong profitability potential [5][56] - **Customer Retention**: The company boasts a 95% retention rate of its customer base year on year, making it difficult for customers to switch suppliers [53] Product Offerings - **Product Categories**: - Catalog products (60% of business) for general R&D and academic use [16] - Custom products (35% of business), with 25% of that being biopharma-related [18] - **Growth in Custom Products**: Custom biopharma products grew by 40% last year, indicating strong demand [18] - **Speed of Delivery**: Technova can deliver research-use products in 2-3 weeks and custom GMP products in 4-8 weeks, significantly faster than competitors who may take 4-8 months [28][29] Competitive Advantage - **Customization and Quality**: Technova focuses on providing high-quality, customized reagents quickly, which is a gap in the market compared to larger players [10][19] - **Modular Manufacturing**: The company employs a modular manufacturing approach, allowing for flexibility in production sizes and formulations [25][27] - **Customer Service**: High levels of customer service and support, reflected in a net promoter score in the seventies [22] Financial Outlook - **Capital Position**: Technova had $26 million in cash at the end of Q1 and an untapped revolving line of credit, providing a solid financial foundation [61] - **Path to Profitability**: Adjusted EBITDA breakeven is expected at $50-55 million in revenue, with cash flow positive anticipated shortly thereafter [62] Industry Context - **Biotech Environment**: The company is navigating a challenging biotech funding environment but continues to gain clinical customers, projecting a 15% growth in this segment by 2025 [52] - **Regulatory Impact**: Technova feels insulated from tariff impacts due to its U.S.-based manufacturing and limited reliance on foreign raw materials [49][50] Future Strategies - **Partnerships and Collaborations**: Technova is looking to expand partnerships, such as the recent collaboration with Pluristics for cryopreservation media, to enhance its product offerings [45][58] - **Focus on Emerging Therapies**: The company aims to support the growing complexity in bioprocessing for therapies like cell and gene therapy, which require more customized solutions [36][39] Conclusion - **Long-term Growth**: Technova is positioned for sustainable growth with a strong foundational business, significant investments already made, and a clear strategy to scale operations without the need for further major investments [47][48]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdiction ...

Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Jennifer Henry - Senior Vice President of MarketingStephen Gunstream - President & CEOMatthew Lowell - Chief Financial OfficerVidyun Bais - Equity Research - Vice PresidentChad Wiatrowski - VP - Equity Research Conference Call Participants Anna Snopkowski - Equity Research AnalystMatthew Hewitt - Senior Research AnalystMatt Larew - Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome t ...

Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Tecnova First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw y ...

FINANCIAL RESULTS: Q1:2025 SLIDE SUPPLEMENT Nasdaq: TKNO May 8, 2025 • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Today's Agenda © 2025 Alpha Teknova, Inc. ● Financial Results | Q1:2025 ● Slide Supplement May 8, 2025 2 Statements in this presentation about future expectations, plans, and prospects, as well as ...

Exhibit 99.1 Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreezeTM cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 8, 2025 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therap ...

First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today an ...

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, after market close, indicating a focus on transparency and communication with investors [1]. Group 1: Financial Reporting - The company will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025 [1]. - A webcast and conference call will be held on the same day at 5 p.m. Eastern Time for investors to access the results [2]. Group 2: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, supporting the life sciences industry [3]. - The company offers customizable solutions for various stages of the workflow, aiding in molecular diagnostics, synthetic biology, and emerging therapeutic modalities [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, designed for efficient production of foundational ingredients for next-generation therapies [3].

Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel t ...

HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading ...